Influence of pHi and creatine phosphate on alpha-adrenoceptor-mediated cardiac hypertrophy.
Stimulation of alpha-adrenoceptors on ventricular cardiomyocytes isolated from adult rat hearts leads to cellular alkalization, increases of creatine phosphate concentration, RNA mass, and protein synthesis. This study investigated whether the increase of creatine phosphate concentrations is causally linked to the hypertrophic response of cardiomyocytes under alpha-adrenoceptor stimulation. Cellular alkalization achieved with phenylephrine (10 microM), an alpha-adrenoceptor agonist, was abolished in the presence of the sodium-proton-exchange (NHE)-inhibitor HOE 694 (1 microM). HOE 694 inhibited also the alpha-adrenoceptor-mediated increase in cellular creatine phosphate and the increase in cellular RNA mass. The phenylephrine-induced stimulation of protein synthesis (determined by incorporation of 14C-phenylalanine) was reduced by one-third when HOE 694 was present. beta-Guanidinopropionic acid was added to cardiomyocytes to reduce cellular creatine phosphate concentrations. In these cultures, alpha-adrenoceptor stimulation activated NHE, but creatine phosphate concentrations were not increased. Protein synthesis was augmented to the same extent as in control cultures, but total RNA mass did not increase. From these results we conclude that alpha-adrenoceptor stimulation causes the increase in protein synthesis via activation of NHE, but independent of the concomitant increase in creatine phosphate contents. The effect of alpha-adrenoceptor stimulation on total RNA mass (translational capacity) is also caused by NHE activation, but depends on the changes in creatine phosphate contents as well.
Schlüter
K D
KD
Physiologisches Institut, Justus-Liebig-Universität Giessen, Germany.
Schäfer
M
M
Balser
C
C
Taimor
G
G
Piper
H M
HM
D000316:Adrenergic alpha-Agonists / Q000494:pharmacology; D000818:Animals; D006332:Cardiomegaly / Q000209:etiology* / Q000378:metabolism; D002455:Cell Division; D002478:Cells, Cultured; D006146:Guanidines / Q000494:pharmacology; D006352:Heart Ventricles / Q000166:cytology; D006863:Hydrogen-Ion Concentration; D008297:Male; D009206:Myocardium / Q000166:cytology; D010656:Phenylephrine / Q000494:pharmacology; D010725:Phosphocreatine / Q000378:metabolism*; D011422:Propionates / Q000494:pharmacology; D014176:Protein Biosynthesis; D012313:RNA; D051381:Rats; D017208:Rats, Wistar; D011942:Receptors, Adrenergic, alpha / Q000378:metabolism*; D017923:Sodium-Hydrogen Exchangers / Q000037:antagonists & inhibitors; D013450:Sulfones / Q000494:pharmacology
D000316:Adrenergic alpha-Agonists; D006146:Guanidines; D011422:Propionates; D011942:Receptors, Adrenergic, alpha; D017923:Sodium-Hydrogen Exchangers; D013450:Sulfones; D010725:Phosphocreatine; C074107:3-methylsulfonyl-4-piperidinobenzoyl guanidine; D010656:Phenylephrine; D012313:RNA; C005775:guanidinopropionic acid